Nirnoy Dan
University of Tennessee Health Science Center
AnabolismEpidemiologyClonogenic assayCancerGene deliveryLipogenesisAbsorption (skin)HelixCellNanomedicineCytotoxic T cellEndoplasmic reticulumVirologyAntibodyPoint mutationLipid signalingBioavailabilityLiposomeChemistryApoptosisStructural biologyAspartate proteaseConjugateEffluxIn vitroMicrovesiclesIn vivoHomeobox protein NANOGVaccinationVirusSurvivinTumor microenvironmentMiddle East respiratory syndromeChemotherapyProteasePlasmepsin IIVincaPaclitaxelMucusEnteric coatingCoronavirusMiddle East respiratory syndrome coronavirusSOX2Cervical cancerCurcuminCyclin B1PancaMatrigelPancreasSTAT3MetastasisDiseaseDrug deliveryAdenosine monophosphateDrugAMPKPancreatic cancerGemcitabineLinkerPathogenesisPlasmepsinKRASExosomeTannic acidChemosensitizationHemoglobin breakdownCell cycleCancer therapyMembrane permeabilityTherapy responseProteolytic enzymesPrion proteinLipid metabolismReactive oxygen speciesMutationCancer researchViability assayTransfectionGeneticsCancer stem cellCarcinogenesisMolecular dynamicsCell growthComputational biologyMedicineDrug discoveryTurn (biochemistry)BiologyCell biologyCancer cellCatabolismProtein kinase APharmacology
14Publications
6H-index
183Citations
Publications 14
Newest
#1Nirnoy Dan (UTHSC: University of Tennessee Health Science Center)H-Index: 6
#2Kamalika Samanta (UTHSC: University of Tennessee Health Science Center)H-Index: 2
Last. Hassan Almoazen (UTHSC: University of Tennessee Health Science Center)H-Index: 8
view all 3 authors...
While each route of therapeutic drug delivery has its own advantages and limitations, oral delivery is often favored because it offers convenient painless administration, sustained delivery, prolonged shelf life, and often lower manufacturing cost. Its limitations include mucus and epithelial cell barriers in the gastrointestinal (GI) tract that can block access of larger molecules including Therapeutic protein or peptide-based drugs (TPPs), resulting in reduced bioavailability. This review desc...
1 CitationsSource
#1Vivek Kumar Kashyap (UTHSC: University of Tennessee Health Science Center)H-Index: 1
#1Vivek K. Kashyap (UTHSC: University of Tennessee Health Science Center)H-Index: 8
Last. Subhash C. Chauhan (UTHSC: University of Tennessee Health Science Center)H-Index: 5
view all 14 authors...
Abstract In this study, we investigated the therapeutic efficacy of VERU-111 in vitro and in vivo model systems of cervical cancer. VERU-111 treatment inhibited cell proliferation and, clonogenic potential, induce accumulation of p53 and down regulated the expression of HPV E6/E7 expression in cervical cancer cells. In addition, VERU-111 treatment also decreased the expression of phosphorylation of Jak2 (TyR1007/1008) and STAT3 at Tyr705 and Ser727. VERU-111 treatment arrested cell cycle in the ...
2 CitationsSource
#1Prashanth K.B. Nagesh (University of Texas at Austin)H-Index: 10
#2Pallabita Chowdhury (UTHSC: University of Tennessee Health Science Center)H-Index: 12
Last. Murali M. Yallapu (University of Texas at Austin)H-Index: 34
view all 9 authors...
Prostate cancer (PCa) cells exploit the aberrant lipid signaling and metabolism as their survival advantage. Also, intracellular storage lipids act as fuel for the PCa proliferation. However, few studies were available that addressed the topic of targeting lipid metabolism in PCa. Here, we assessed the tannic acid (TA) lipid-targeting ability and its capability to induce endoplasmic reticulum (ER) stress by reactive oxygen species (ROS) in PCa cells. TA exhibited dual effects by inhibiting lipog...
5 CitationsSource
#1Nirnoy Dan (UTHSC: University of Tennessee Health Science Center)H-Index: 6
#2Sheema Khan (UTHSC: University of Tennessee Health Science Center)H-Index: 23
Last. Subhash C. Chauhan (UTHSC: University of Tennessee Health Science Center)H-Index: 49
view all 9 authors...
Background: Although, surgical resection and chemotherapy are the gold standard for treating pancreatic cancer (PanCa), poor patient survival remains the problem. Despite being one of the most common oncogenes in human cancer, to date, no success has been achieved to inhibit KRAS. Targeting KRAS has been shown to synergize anti-cancer activity of gemcitabine in pancreatic cancer. Herein, we have developed a supermagnetic iron oxide (SP) nanoparticles for the sustained delivery of KRAS siRNA to t...
Source
#1Kamalika SamantaH-Index: 2
#2Sheema Khan (UTHSC: University of Tennessee Health Science Center)H-Index: 23
Last. Subhash Chandra Chauhan (UTHSC: University of Tennessee Health Science Center)H-Index: 1
view all 8 authors...
Background-Pancreatic cancer (PanCa) is the third deadliest cancer in United States with a poor survival rate. Despite extensive research efforts, there is no substantial progress in cancer therapeutics due to barrier against intracellular drug delivery. Our group has previously identified that microRNA-145 (miR-145) is downregulated in PanCa, the restoration of which inhibits tumor growth and enhances gemcitabine sensitivity. However, lack of an effective tumor-specific delivery system remains ...
Source
#1Sheema Khan (UTHSC: University of Tennessee Health Science Center)H-Index: 23
#2Saini Setua (UTHSC: University of Tennessee Health Science Center)H-Index: 7
Last. Subhash C. Chauhan (UTHSC: University of Tennessee Health Science Center)H-Index: 49
view all 14 authors...
Abstract Pancreatic cancer is a complex disease accounting for fibrotic tumors and an aggressive phenotype. Gemcitabine (GEM) is used as a standard therapy, which develops chemoresistance leading to poor patient outcome. We have recently developed a superparamagnetic iron oxide nanoparticle (SPION) formulation of curcumin (SP-CUR), which is a nontoxic, bioactive anti-inflammatory/anti-cancer agent for its enhanced delivery in tumors. In this study, we demonstrate that SP-CUR effectively delivers...
24 CitationsSource
#1Saini SetuaH-Index: 7
#2Sheema KhanH-Index: 23
Last. Subhash C. ChauhanH-Index: 49
view all 8 authors...
Source
#1Pallabita Chowdhury (UTHSC: University of Tennessee Health Science Center)H-Index: 12
#2Prashanth K.B. Nagesh (UTHSC: University of Tennessee Health Science Center)H-Index: 10
Last. Murali M. Yallapu (UTHSC: University of Tennessee Health Science Center)H-Index: 34
view all 12 authors...
Abstract Paclitaxel (PTX) is a gold standard chemotherapeutic agent for breast, ovarian, pancreatic and non-small cell lung carcinoma. However, in clinical use PTX can have adverse side effects or inadequate pharmacodynamic parameters, limiting its use. Nanotechnology is often employed to reduce the therapeutic dosage required for effective therapy, while also minimizing the systemic side effects of chemotherapy drugs. However, there is no nanoformulation of paclitaxel with chemosensitization mo...
29 CitationsSource
#1Vivek K. Kashyap (UTHSC: University of Tennessee Health Science Center)H-Index: 8
#2Bilal Bin Hafeez (UTHSC: University of Tennessee Health Science Center)H-Index: 28
Last. Subhash C. Chauhan (UTHSC: University of Tennessee Health Science Center)H-Index: 49
view all 15 authors...
Objective: Cervical cancer is one of the most common and deadly cancers among women worldwide and is associated with persistent Human Papillomavirus (HPV) infection. Human papilloma virus (HPV) expressing E6 and E7 oncoproteins involved in carcinogenesis through their interactions with the p53 and pRB pathways, respectively. Therefore, non-toxic agents that have potential to inhibit the expression of E6 and E7 oncoproteins and their regulated oncogenic signaling pathways could be used in the man...
Source
#1Nirnoy Dan (UTHSC: University of Tennessee Health Science Center)H-Index: 6
#2Saini Setua (UTHSC: University of Tennessee Health Science Center)H-Index: 7
Last. Subhash C. Chauhan (UTHSC: University of Tennessee Health Science Center)H-Index: 49
view all 7 authors...
Chemotherapy is one of the major therapeutic options for cancer treatment. Chemotherapy is often associated with a low therapeutic window due to its poor specificity towards tumor cells/tissues. Antibody-drug conjugate (ADC) technology may provide a potentially new therapeutic solution for cancer treatment. ADC technology uses an antibody-mediated delivery of cytotoxic drugs to the tumors in a targeted manner, while sparing normal cells. Such a targeted approach can improve the tumor-to-normal t...
82 CitationsSource